The phase 3 clinical trial is a prospective, double-blind, randomized multicenter study in the United States. The trial includes placebo and midazolam controls.
Patient recruitment for the study is expected to reach completion in 2016.
More articles on gastroenterology:
Consumerism is taking healthcare by storm: How is GI affected?
3 GI physicians making headlines – June 5, 2015
EndoChoice IPO update: Common stock price set at $15 per share
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
